Your browser doesn't support javascript.
Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19.
Praveen, D; Puvvada, Ranadheer Chowdary; M, Vijey Aanandhi.
  • Praveen D; Research Scholar, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, 600117, Chennai, India. Electronic address: praveennandan.1993@gmail.com.
  • Puvvada RC; Research Scholar, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, 600117, Chennai, India. Electronic address: ranadheer.pharmd@gmail.com.
  • M VA; Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, Chennai, India. Electronic address: hodpchemistry@velsuniv.ac.in.
Int J Antimicrob Agents ; 55(5): 105967, 2020 May.
Article in English | MEDLINE | ID: covidwho-99031
ABSTRACT
The Wuhan outbreak of novel Corona virus infection has been the global focus since December 2019. This infection has become a global pandemic. It is highly important to understand the virology of the pathogen and to explore the therapeutic options for management of this pandemic. Drug repurposing strategies are being considered for management of COVID 19. Among the identified drugs, Baricitinib has become a keen interest for researchers because of its ability to inhibit the viral assembly by the prevention of Clarithrin associated endocytosis. We tried to explore the reasons on why Baricitinib is not an ideal option for COVID 19.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Betacoronavirus Limits: Humans Language: English Journal: Int J Antimicrob Agents Year: 2020 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Betacoronavirus Limits: Humans Language: English Journal: Int J Antimicrob Agents Year: 2020 Document Type: Article